Brief: Synact Pharma Q3 Pretax Loss Widens To SEK 9.1 Million
13/11/2020 08:46
Nov 13 (Reuters) - SynAct Pharma AB SYNACT.TE :
* Q3 PRETAX LOSS SEK 9.1 MILLION VERSUS LOSS SEK 3.6 MILLION
YEAR
AGO
Source text for Eikon: ID:nWkr67Hbfm
Further company coverage: SYNACT.TE
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on SynAct Pharma AB
See all newsSweden's SynAct Pharma Q3 net loss narrows as expenses fall
Brief: SynAct Pharma Q3 Net Income SEK -32.177 Million
Brief: SynAct Pharma Signs First Commercial Partnership For Resomelagon
Brief: WHO Names Resomelagon Among Key Dengue Drug Candidates
Brief: SynAct Pharma Says Advance Analysis Supports Phase 3 Development